Satoru Muto1,2, Masahiko Ando3, Saori Nishio4, Kazushige Hanaoka5, Yoshifumi Ubara6, Ichiei Narita7, Kouichi Kamura8, Toshio Mochizuki9,10, Ken Tsuchiya11, Kazuhiko Tsuruya12, Shigeo Horie13,14. 1. Department of Advanced Informatics for Genetic Disease, Juntendo University Graduate School of Medicine, Tokyo, Japan. s-muto@juntendo.ac.jp. 2. Department of Urology, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. s-muto@juntendo.ac.jp. 3. Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan. 4. Department of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. 5. Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan. 6. Department of Nephrology, Toranomon Hospital, Tokyo, Japan. 7. Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. 8. Department of Urology, Chiba East Hospital, Chiba, Japan. 9. Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan. 10. Clinical Research Division for Polycystic Kidney Disease, Department of Medicine, Tokyo Women's Medical University, Tokyo, Japan. 11. Department of Blood Purification, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan. 12. Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 13. Department of Advanced Informatics for Genetic Disease, Juntendo University Graduate School of Medicine, Tokyo, Japan. 14. Department of Urology, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Abstract
BACKGROUND: Although it is widely accepted that the autosomal dominant polycystic kidney disease (ADPKD) patients with large liver cysts have a significant decrement in quality of life (QOL), there is insufficient evidence that clearly demonstrates the relationship between the size of the liver cysts and QOL. Therefore, we started this prospective longitudinal study to investigate the impact of liver cysts on QOL. METHODS: We grouped the 111 included ADPKD patients into 4 groups (control group A; < 25%, group B; 25-49%, group C; 50-75%, group D; > 75%) according to liver cysts-parenchyma ratio (CPR). QOL was measured by FANLTC + FACT-Hep scores. We compared QOL scores and several clinical parameters amongst these groups for 3 years. RESULTS: The number of patients in group A, B, C, and D was 31, 14, 14, and 23, respectively. Although there were no significant differences in AST (p = 0.107), ALT (p = 0.925), and serum albumin (p = 0.212) between the four groups, platelet count was significantly decreased along with the extension of cyst volume (p = 0.030). Overall, the mean FANLTC and FACT-Hep scores were 71.8 ± 12.5, and 32.4 ± 5.8, respectively. FANLTC (p = 0.017) and FACT-Hep scores (p = 0.003) were significantly decreased with increasing cyst volume. From the data collected at the time of registration, multivariate linear regression analysis demonstrated that the CPR had a significant influence on FANLTC and FACT-Hep scores. CONCLUSION: In this cross-sectional and prospective longitudinal study, we demonstrate the relationship between liver cyst volume and QOL in ADPKD patients. We hope to establish the long-term influence on QOL in this ongoing prospective longitudinal study.
BACKGROUND: Although it is widely accepted that the autosomal dominant polycystic kidney disease (ADPKD) patients with large liver cysts have a significant decrement in quality of life (QOL), there is insufficient evidence that clearly demonstrates the relationship between the size of the liver cysts and QOL. Therefore, we started this prospective longitudinal study to investigate the impact of liver cysts on QOL. METHODS: We grouped the 111 included ADPKDpatients into 4 groups (control group A; < 25%, group B; 25-49%, group C; 50-75%, group D; > 75%) according to liver cysts-parenchyma ratio (CPR). QOL was measured by FANLTC + FACT-Hep scores. We compared QOL scores and several clinical parameters amongst these groups for 3 years. RESULTS: The number of patients in group A, B, C, and D was 31, 14, 14, and 23, respectively. Although there were no significant differences in AST (p = 0.107), ALT (p = 0.925), and serum albumin (p = 0.212) between the four groups, platelet count was significantly decreased along with the extension of cyst volume (p = 0.030). Overall, the mean FANLTC and FACT-Hep scores were 71.8 ± 12.5, and 32.4 ± 5.8, respectively. FANLTC (p = 0.017) and FACT-Hep scores (p = 0.003) were significantly decreased with increasing cyst volume. From the data collected at the time of registration, multivariate linear regression analysis demonstrated that the CPR had a significant influence on FANLTC and FACT-Hep scores. CONCLUSION: In this cross-sectional and prospective longitudinal study, we demonstrate the relationship between liver cyst volume and QOL in ADPKDpatients. We hope to establish the long-term influence on QOL in this ongoing prospective longitudinal study.
Entities:
Keywords:
Autosomal dominant polycystic kidney disease; Liver cyst volume; Quality of life
Authors: Krista L Lentine; Huiling Xiao; Gerardo Machnicki; Adrian Gheorghian; Mark A Schnitzler Journal: Clin J Am Soc Nephrol Date: 2010-06-10 Impact factor: 8.237
Authors: Nancy Heffernan; David Cella; Kimberly Webster; Linda Odom; Mary Martone; Steven Passik; Marilyn Bookbinder; Yuman Fong; William Jarnagin; Leslie Blumgart Journal: J Clin Oncol Date: 2002-05-01 Impact factor: 44.544